{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:51:42Z","timestamp":1740135102909,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p><jats:italic>Pneumocystis carinii<\/jats:italic>pneumonia (PCP) prophylaxis is recommended after hematopoietic stem cell transplantation (HSCT). In patients who are unable to take first-line prophylaxis, trimethoprim\/sulfamethoxazole, aerosolized pentamidine is recommended. This drug may not, however, be available at all institutions, and its administration requires special techniques. Therefore, intravenous pentamidine (IVP) has been used in adult patients as an alternative, despite limited data. We evaluated the effectiveness and tolerability of IVP for PCP prophylaxis in adult patients who had undergone HSCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A single-center retrospective study was conducted of adult patients who had undergone allogenic or autologous HSCT between January 2014 and September 2018 and had received at least three doses of IVP for PCP prophylaxis. The IVP dose was 4\u2009mg\/kg administered monthly. Data on PCP infection and adverse reactions were collected from both patients\u2019 electronic medical records and the pharmacy adverse drug reactions documentation system. Patients were followed from the start of IVP up to 6\u2009months after discontinuation of therapy. A confirmed PCP infection was defined as radiographic evidence of PCP and positive staining of a respiratory specimen. Descriptive statistics were used to analyze the study outcomes<jats:bold>.<\/jats:bold><\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the study period, 187 patients were included. The median age was 36.4\u2009years (range, 18\u201364), 58% were male, and 122 (65%) had received allogeneic HSCT while the remainder autologous HSCT. The median number of IVP doses administered per patient was 5 (range, 3\u201329). During the study period, none of the patients had evidence of confirmed PCP infection. However; there were two cases with high clinical suspicion of PCP infection (i.e. required anti-pneumocystis therapy) and one reported case of central nervous system toxoplasmosis while receiving IVP for PCP prophylaxis. Only one case of nausea associated with IVP administration was reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In a cohort of adult patients with HSCT who received IVP for PCP prophylaxis, there was no evidence of confirmed PCP infection, and the treatment appeared to be well tolerated. Prospective studies should be conducted to confirm the efficacy and tolerability of IVP.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-020-05127-y","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T20:02:46Z","timestamp":1591387366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness and tolerability of intravenous pentamidine for Pneumocystis carinii pneumonia prophylaxis in adult hematopoietic stem cell transplant patients: a retrospective study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7854-4970","authenticated-orcid":false,"given":"Wedad B.","family":"Awad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Asaad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nardin","family":"Al-Yasein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rula","family":"Najjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"5127_CR1","doi-asserted-by":"crossref","unstructured":"Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th edition. Elsevier Inc.; 2010.","DOI":"10.1071\/SHv7n2_BR3"},{"key":"5127_CR2","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMra032588","volume":"350","author":"CF Thomas Jr","year":"2004","unstructured":"Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487\u201398.","journal-title":"N Engl J Med"},{"key":"5127_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/tid.12486","volume":"18","author":"R Diri","year":"2016","unstructured":"Diri R, Anwer F, Yeager A, Krishnadasan R, McBride A. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2016;18:63\u20139.","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"5127_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/sj.bmt.1705149","volume":"36","author":"N De Castro","year":"2005","unstructured":"De Castro N, Neuville S, Sarfati C, Ribaud P, Derouin F, Gluckman E, et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant. 2005;36(10):879\u201383.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"5127_CR5","first-page":"267","volume":"10","author":"IZ Tuan","year":"1992","unstructured":"Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant. 1992;10(3):267\u201372.","journal-title":"Bone Marrow Transplant"},{"issue":"RR-10","key":"5127_CR6","first-page":"1","volume":"49","author":"Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation","year":"2000","unstructured":"Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000;49(RR-10):1\u2013125.","journal-title":"MMWR Recomm Rep"},{"issue":"9","key":"5127_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkw157","volume":"71","author":"J Maertens","year":"2016","unstructured":"Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):1\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"5127_CR8","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","volume":"15","author":"M Tomblyn","year":"2009","unstructured":"Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143\u2013238.","journal-title":"Biol Blood Marrow Transplant"},{"key":"5127_CR9","unstructured":"National Comprehensive Cancer Network. Prevention and Treatment of Cancer-related Infections [Version.1.2020]. (Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf, Accessed 24 Jan 2020)."},{"issue":"1","key":"5127_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1083-8791(00)70050-4","volume":"6","author":"MJ Vasconcelles","year":"2000","unstructured":"Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant. 2000;6(1):35\u201343.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"5127_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/pbc.21287","volume":"50","author":"SY Kim","year":"2008","unstructured":"Kim SY, Dabb AA, Glenn JD, Snyder KM, Chuk MK, Loeb DM. Intravenous pentamidine is effective as second line pneumocystis pneumonia prophylaxis in pediatric oncology patients. Pediatric Blood Cancer. 2008;50(4):779\u201383.","journal-title":"Pediatric Blood Cancer"},{"issue":"4","key":"5127_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/bmt.2015.316","volume":"51","author":"KM Williams","year":"2016","unstructured":"Williams KM, Ahn KW, Chen M, Aljurf MD, Agwu AL, Chen AR, et al. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplant. 2016;51(4):573\u201380.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"5127_CR13","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/bmt.2016.133","volume":"51","author":"DA Curi","year":"2016","unstructured":"Curi DA, Duerst RE, Badke C, Bell J, Chaudhury S, Kletzel M, et al. IV pentamidine for Pneumocystis jiroveci pneumonia prophylaxis in pediatric allogeneic stem cell transplant patients. Bone Marrow Transplant. 2016;51(10):1394\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"5127_CR14","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1097\/MPH.0000000000000584","volume":"38","author":"LJ Solodokin","year":"2016","unstructured":"Solodokin LJ, Klejmont LM, Scipione MR, Dubrovskaya Y, Lighter-Fisher J, Papadopoulos J. Safety and effectiveness of intravenous pentamidine for prophylaxis of Pneumocystis jirovecii pneumonia in pediatric hematology\/oncology patients. J Pediatr Hematol Oncol. 2016;38(6):e180\u20135.","journal-title":"J Pediatr Hematol Oncol"},{"key":"5127_CR15","unstructured":"Burroughs G, Connor T, McDiarmid M. NIOSH alert: preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings DHHS (NIOSH) (Publ. No. 2004-165). Cincinnati; 2004. p. 58. Available from: https:\/\/www.cdc.gov\/niosh\/docs\/2004-165\/pdfs\/2004-165.pdf, Accessed 24 Jan 2020]."},{"issue":"3","key":"5127_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41409-017-0024-1","volume":"53","author":"K Sweiss","year":"2018","unstructured":"Sweiss K, Anderson J, Wirth S, Oh A, Quigley JG, Khan I, et al. A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant. Bone Marrow Transplant. 2018;53(3):300\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"5127_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00173-18","volume":"62","author":"M Quinn","year":"2018","unstructured":"Quinn M, Fannin JT, Sciasci J, Bragg A, Campbell PK, Carias D, et al. Pentamidine for prophylaxis against Pneumocystis jirovecii pneumonia in pediatric oncology patients receiving immunosuppressive chemotherapy. Antimicrob Agents Chemother. 2018;62(8):e00173.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"5127_CR18","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/INF.0b013e318292f560","volume":"32","author":"J DeMasi","year":"2013","unstructured":"DeMasi J, Cox J, Leonard D, Koh A, Aquino V. Intravenous pentamidine is safe and effective as primary Pneumocystis pneumonia prophylaxis in children and adolescents undergoing hematopoietic stem cell transplantation. Pediatr Infect Dis J. 2013;32(9):933\u20136.","journal-title":"Pediatr Infect Dis J"},{"key":"5127_CR19","unstructured":"Drug information: pentamidine (systemic). Lexicomp: http:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/multinat_f\/5873117?cesid=7FVU8wrSNpB&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPentamidine%2520%26t%3Dname%26va%3DPentamidine%2520#adr. Accessed 5 Apr 2020."},{"key":"5127_CR20","unstructured":"Drug information: Intravenous pentamidine. Electronic medicines compendium: https:\/\/www.medicines.org.uk\/emc\/product\/977. Accessed 5 Apr 2020."},{"issue":"9","key":"5127_CR21","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1128\/JCM.01480-14","volume":"52","author":"F Robert-Gangneux","year":"2014","unstructured":"Robert-Gangneux F, Belaz S, Revest M, Tattevin P, Jouneau S, Decaux O, et al. Diagnosis of Pneumocystis jirovecii pneumonia in immunocompromised patients by real-time PCR: a 4-year prospective study. J Clin Microbiol. 2014;52(9):3370\u20136.","journal-title":"J Clin Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05127-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05127-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05127-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T21:29:01Z","timestamp":1666819741000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05127-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5127"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05127-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"19 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Institutional Review Board of King Hussein Cancer Center, Amman-Jordan under the reference number of 19KHCC51, and the Institutional Review Board granted the permission to access the raw data and patients\u2019 electronic medical records. The raw data that was obtained from the bone marrow transplant unit database and pharmacy billing system was identified to the corresponding authors: WA, RN, NA and AA for data collection. The included data was then coded and was anonymous to the data analysis personnel. A waiver of consent was submitted to access the retrospective data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"400"}}